JustInvest LLC Has $2.82 Million Holdings in Eli Lilly and Company (NYSE:LLY)


Share on StockTwits

JustInvest LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 35.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,103 shares of the company’s stock after purchasing an additional 3,964 shares during the period. JustInvest LLC’s holdings in Eli Lilly and were worth $2,822,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Perennial Advisors LLC acquired a new stake in shares of Eli Lilly and in the 4th quarter valued at $31,000. DB Wealth Management Group LLC bought a new position in Eli Lilly and in the 4th quarter worth $34,000. Retirement Group LLC bought a new position in Eli Lilly and in the 4th quarter worth $33,000. Archer Investment Corp raised its holdings in Eli Lilly and by 83.3% in the 4th quarter. Archer Investment Corp now owns 220 shares of the company’s stock worth $37,000 after acquiring an additional 100 shares during the period. Finally, Accel Wealth Management bought a new position in Eli Lilly and in the 4th quarter worth $37,000. 75.59% of the stock is owned by institutional investors and hedge funds.

In related news, CAO Donald A. Zakrowski sold 3,000 shares of the stock in a transaction on Wednesday, April 28th. The shares were sold at an average price of $181.38, for a total transaction of $544,140.00. Following the completion of the transaction, the chief accounting officer now owns 5,987 shares in the company, valued at $1,085,922.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jackson P. Tai bought 1,366 shares of Eli Lilly and stock in a transaction that occurred on Friday, April 30th. The shares were acquired at an average price of $182.84 per share, with a total value of $249,759.44. Following the acquisition, the director now directly owns 60,649 shares of the company’s stock, valued at approximately $11,089,063.16. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.

Several research analysts recently commented on LLY shares. Morgan Stanley dropped their target price on shares of Eli Lilly and from $217.00 to $207.00 and set an “overweight” rating on the stock in a report on Tuesday. Barclays dropped their price objective on shares of Eli Lilly and from $232.00 to $227.00 and set an “overweight” rating on the stock in a report on Tuesday. Truist Securities boosted their price objective on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, March 22nd. Mizuho dropped their price objective on shares of Eli Lilly and from $228.00 to $216.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Truist boosted their price objective on shares of Eli Lilly and from $200.00 to $215.00 in a report on Monday, February 1st. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $200.75.

NYSE:LLY traded up $1.96 during trading hours on Tuesday, hitting $187.88. The stock had a trading volume of 52,264 shares, compared to its average volume of 4,094,015. Eli Lilly and Company has a one year low of $129.21 and a one year high of $218.00. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36. The company has a market cap of $180.18 billion, a price-to-earnings ratio of 30.38, a P/E/G ratio of 1.57 and a beta of 0.37. The business’s 50 day moving average is $185.84 and its 200-day moving average is $176.06.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Monday, April 26th. The company reported $1.87 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.12 by ($0.25). Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm had revenue of $6.81 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the previous year, the company posted $1.75 EPS. The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. On average, sell-side analysts anticipate that Eli Lilly and Company will post 7.56 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 10th. Stockholders of record on Friday, May 14th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 1.81%. Eli Lilly and’s dividend payout ratio is 56.29%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also: Initial Coin Offerings entail a high degree of risk

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.